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Abstract:  The turbulent history of clinical trials in viral gene therapy has taught us 
important lessons about vector design and safety issues. Much effort was spent on 
analyzing genotoxicity after somatic integration of therapeutic DNA into the host genome. 
Based on these findings major improvements in vector design including the development 
of viral hybrid vectors for somatic integration have been achieved. This review provides a 
state-of-the-art overview of available hybrid vectors utilizing viruses for high transduction 
efficiencies in concert with various integration machineries for random and targeted 
integration patterns. It discusses advantages but also limitations of each vector system.  
Keywords:  hybrid vector; somatic integration; adenovirus; retrovirus; adeno-associated 
virus; herpes simplex virus; targeted integration; Sleeping Beauty transposase; PhiC31 
integrase; zinc-finger nuclease 
 
1. Introduction 
The development of novel and safer vector tools for stable maintenance of therapeutic DNA and 
transgene products within a cell, especially in rapidly dividing cells (e.g., bone marrow derived cells), 
is of great interest to the research community. For instance therapies for these genetic diseases would 
benefit from such tools because they rely on stable production of the defective gene product and 
subsequent long-term phenotypic correction. Furthermore, these vectors would circumvent repeated 
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vector administration necessary for life-long correction. Moreover, inconveniences for the patient due 
to repeated drug administration could be avoided.  
Recombinant viral vectors commonly used for stable gene transfer can be divided by their ability to 
either integrate foreign DNA into the host genome or by their capability to be maintained as episomal, 
non-integrative viral vector genomes. However, until now none of the commonly used vector systems 
for maintenance of therapeutic DNA in dividing cells is optimal: (i) the development of episomally 
maintained DNA molecules, although without any risk of insertional mutagenesis, remains a 
challenging task. Limiting features are insufficient retention and replication of the episomal viral   
(e.g., adenovirus and adeno-associated virus [AAV]) or non-viral (plasmid replicon) DNA molecule 
during cell division, inefficient delivery of replicating DNA, and the involvement of potential toxic 
viral coding products which in many cases are prerequisites for DNA retention within the nucleus. (ii) 
Integrating viral vectors were tested in preclinical and clinical settings and gathered information 
revealed that integration site preferences may cause genotoxicity by changing the expression profile 
and properties of the transduced target cell due to insertional mutagenesis. Therefore, one obvious 
approach to improve stable gene transfer for therapeutic applications is improving target site selection 
of integrating viral vectors by specifying their integration site preferences. To accomplish this goal, 
one solution could be the generation of viral hybrid vectors. Viral hybrid vectors are defined as vectors 
which combine the high transduction rates of viruses with genetic elements for stable maintenance of 
therapeutic DNA.  
Figure 1. Principle of integrating viral hybrid vectors. Viral hybrid vectors combine 
efficient transduction rates of viruses (delivering vector) with improved genetic elements 
for stable maintenance of therapeutic DNA by somatic integration into the host genome of 
the target cell.  
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This article focuses on recombinant viral hybrid vectors with the ability to integrate their 
therapeutic DNA into the host genome of eukaryotic cells. The principle of integrating viral hybrid 
vectors is schematically shown in Figure 1. It is based on combining high efficiency gene transfer of 
viral vectors with the most advanced integration machineries. Herein, we describe the state-of-the-art 
of hybrid vector technologies for increased and safer integration of therapeutic DNA into the host 
genome and we discuss the advantages but also limitations for each single vector system. 
Table 1. State-of-the-art of hybrid vector technologies. The mentioned delivery systems 
are helper-dependent adenovirus (HDAdV), herpes simplex virus type 1 (HSV-1), 
retrovirus (RV), and integrase defective lentivirus (IDLV). Integration machineries used in 
combination with these delivery vehicles are Sleeping Beauty (SB) transposase, 
bacteriophage integrase PhiC31, retrotransposon, adeno-associated virus (AAV; AAV-ITR 
or AAV-Rep protein-mediated), retrovirus (RV; LTR-mediated or retrovirus integrase 
mediated), zinc-finger nuclease (ZFN), and DNA-binding domain-retroviral integrase-
fusion proteins (DBD-IN fusion proteins). (+) represents the existing combination of the 
respective integration machineries and the delivering vector. (-) represents non-existing 
viral hybrid vector systems.  
 
 
The number of different hybrid vectors which are under development as gene-therapeutic 
integrating hybrid vectors is steadily increasing (Table 1. and 2.). Mainly, integrating viral hybrid 
vectors can be distinguished by their viral delivery vehicle and the utilized integration machinery. 
With respect to the delivery vehicle, previous studies have employed adenovirus, herpes simplex   
virus 1 (HSV-1), and retrovirus. Regarding the integration machinery, hybrid vectors can be 
subdivided into two groups according to how their genome integrates, by viral integration systems 
(AAV, retrovirus) or non-viral systems for integration (Sleeping Beauty [SB] transposase [1], 
bacteriophage integrase PhiC31 [2,3], and zinc-finger nucleases [ZFNs] [4,5]).  All integration Viruses 2009, 1  
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machineries are suitable tools for the generation of hybrid vectors because they allow stable and long-
lasting transgene expression in dividing cells.  
Table 2. Overview of currently used hybrid vector systems. The first column indicates the 
viral hybrid vector system for stable integration into the host genome. For each system the 
integration system and the integration pattern (random versus site-specific) are mentioned 
and the respective references are summarized. HDAdV: helper-dependent adenovirus, 
HSV-1: herpes simplex virus type 1, RV: retrovirus, IDLV: integrase defective lentivirus, 
SB: Sleeping Beauty transposase, PhiC31: bacteriophage-derived integrase PhiC31, AAV: 
adeno-associated virus, AAV-Rep: AAV-derived Rep coding sequence responsible for 
site-specific integration into AAVS1, ZFN: zinc-finger nuclease, DBD-IN fusion proteins: 
DNA-binding domain-retroviral integrase-fusion proteins.  
 
Integrating hybrid vectors are an attractive choice if stable alterations need to be maintained in 
dividing cells. Each of these different integrating viral hybrid vectors is characterized by a set of 
different properties coming from the delivering vector itself and the integration machinery which is 
used, that make it suitable for some applications in gene therapy and unsuitable for others. Herein, we 
classified the hybrid vector by its delivery vehicle (adenovirus, herpes simplex virus 1, retrovirus) and 
subdivided the respective group depending on the integration machinery employed (Table 1.).  Viruses 2009, 1  
 
1299
2. Adenovirus-based hybrid vectors for somatic integration 
Adenoviruses are non-enveloped viruses with an icosahedral capsid. The length of the linear, 
double-stranded adenoviral DNA genome is 26 to 45 kilobase (kb) in size [6]. Adenoviruses were 
isolated from various species and human adenoviruses belong to the genus Mastadenoviridae. Until 
now, 53 human adenoviral serotypes were identified which were divided into 6 subgroups (A-F). They 
display a very diverse and broad cellular tropism after in vivo application making them very attractive 
for gene transfer studies.  
Recombinant adenoviral vectors (rAdVs) commonly used in gene transfer applications are usually 
replication-deficient and devoid of one or more essential genes. Based on the current knowledge, 
rAdVs predominantly persist as episomal, replication inactive vector molecules [7]. Integration 
efficiencies of rAdVs with approximately 10
-4 to 10
-6 integration events per infectious genome are 
rather low [8]. However, it is important to point out that in principle, adenovirus has the potential to 
integrate into the host genome of the infected cell. For instance human adenovirus serotype 12 
integrates into the host genome and it shows transforming potential in rodents [9-11]. 
To date, recombinant adenoviral vector systems are the most efficient vectors for transferring genes 
into a large proportion of cells in vitro and in vivo [12]. Different recombinant adenoviral vectors have 
been developed with various regions of viral coding region removed [13]. Early first and second 
generation adenoviral vectors deleted for one (E1 gene) or several genes (E2a, E2b or E4) still result in 
cytotoxicity, because low-level transcription of viral genes from these adenoviral vectors served as 
potent antigene resulting in an effective host immune response [14-16]. The further development of 
helper-dependent adenoviral vectors (HDAdVs) significantly improved the toxicity and 
immunogenicity profiles of adenoviral vectors [14,17]. HDAdVs lack all viral coding sequences and 
the only adenoviral sequences left are the inverted terminal repeats (ITRs) and the packaging signal. 
The HDAdV production process splits the actual therapeutic gene to be transferred to one vector and 
the viral genes required for vector replication and production in a second helper virus vector whose 
packaging signal is flanked by Cre recombinase recognition (loxP) site [18]. In cells expressing the 
Cre protein, the packaging signal is excised from the helper virus genome and the therapeutic vector 
genome is preferentially packaged. In addition, due to the deletion of all viral genes, HDAdV has a 
high cloning capacity up to 37 kb. However, even for HDAdV there is some toxicity related to the 
incoming viral capsid proteins [19]. Duration of transgene expression after adenoviral gene transfers 
various. It depends on the promoter driving transgene expression [20], the delivery method [21], and 
the mouse strain and its immunological background [22], and at least in part on cell division and 
subsequent reduction of episomal vector genomes [23]. Therefore, the development of integrating 
adenoviral hybrid vectors would be one potential solution for achieving long-term transgene 
expression especially for cells with a high turnover.  
The history of integrating adenoviral hybrid vectors for stabilized gene transfer is long and a variety 
of hybrid vectors have been emerging. They combine the highly efficient DNA delivery of adenoviral 
vectors with the integrating machinery of transposons (HDAdV/retrotransposon [24], 
HDAdV/Sleeping Beauty transposon [25]), phage integrases (HDAdV/PhiC31 [26]), retroviruses   
(E1-deleted AdV/RV [27,28]), or adeno-associated virus (HDAdV/AAV [29-31])  (Table 2.). A 
summary of all integrating hybrid vectors based on adenovirus as a delivery vehicle is displayed in 
Figure 2. The following section will provide further details on each single hybrid vector system. Viruses 2009, 1  
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Figure 2. Schematic diagram of all integrating hybrid vector systems based on helper- dependent 
adenoviral vectors (HDAdV) as delivery vehicles (i-v). The transgene expression cassette (shown in 
green) and components for somatic integration are co-delivered using the recombinant adenoviral 
vector. Virus-based integration machineries are shown in the left panel and integration machineries 
based on non-viral systems are displayed in the right panel. (i) HDAdV/adeno-associated virus (AAV) 
hybrid vectors integrate into the host genome randomly via AAV internal terminal repeats (ITRs). 
Rep-Protein expressed in trans provided by a second vector mediates site-specific integration after 
binding to AAV-ITRs and to the AAV integration site S1 (AAVS1), located on the human 
chromosome 19. (ii) HDAdV/retrovirus (RV) hybrid vectors integrate transgene expression cassettes 
flanked by retroviral long terminal repeats (LTRs) directly or after circularization from the adenoviral 
vector genome mediated by Cre recombinase provided in trans. When the retroviral integrase (IN) is 
supplied in trans, the integration complex triggers the random insertion of the transgene into the host 
genome. (iii) For HDAdV/Sleeping Beauty (SB) transposase hybrid vectors the transgene is flanked by 
inverted repeats (IR) as a recognition site for the Sleeping Beauty (SB) transposase. SB is provided in 
trans together with Flp recombinase. When Flp mediates circularization of the DNA and therefore 
mobilization of the transposon from the HDAdV genome, SB binds to the recognition sites and 
integrates the transposon including the transgene randomly into the TA-sites of the host genome. This 
process is reversible. (iv) For the HDAdV/PhiC31 integrase hybrid vector system, the vector DNA 
harbours the PhiC31 recognition site attB within the therapeutic transgene. When PhiC31 protein is 
provided in trans, it mediates integration into a limited number of pseudo attP sites in the mammalian 
genome by unidirectional recombination. The circular form of the PhiC31 substrate is released from 
the adenoviral vector genome by Flp recombinase. At the time it is not clear whether this step is 
required. (v) Retrotransposition from the adenoviral vector genome is based on the interspersed 
element L1. After transduction of the target cell L1 and transgene is described and RNA leads to the 
generation of ribonucleoprotein structure in the cytoplasm. This complex is then imported into the 
nucleus for somatic integration into a consensus genomic target DNA. 
 Viruses 2009, 1  
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2.1. Adenovirus/AAV hybrid vectors.  
One of the earliest studies unified the advantageous gene delivery features of a first generation  
E1-deleted adenoviral vector with the AAV genome simply for production of recombinant AAV 
(rAAV) [32]. Afterwards Ad/AAV hybrids were mainly generated for developing novel gene therapy 
vectors and in particular also for achieving site-specific integration into the host genome. Responsible 
for the unique ability of AAV to integrate into a specific locus on human chromosome 19q13.3-qtr 
(called AAVS1) are the inverted terminal repeat (ITR) in cis and the Rep proteins (Rep68 or Rep78) in 
trans [33-35]. Rep68/78 bind to the Rep-binding site located on both, the AAV genome and the 
genomic AAVS1 pre-integration site. Subsequently, a non-homologous deletion-insertion 
recombination results in the integration of 2-4 copies of the AAV-ITR-cassette [33,35]. In the absence 
of Rep proteins, AAV genomes show a bias towards integration into actively transcribed genes [36]. 
Notably, rAAV vector genomes do not rely on integration into the host genome. In fact, there is 
evidence that integrated as well as extrachromosomal rAAV DNA molecules are responsible for 
transgene expression [37].  
The molecular design of Ad/AAV hybrid vectors is very diverse. Basically, they can be divided into 
two groups of which one group utilizes AAV-Rep protein for site-specific integration and the other 
group is based on Rep-independent rAAV genome integration (Figure 2. i). With respect to the latter 
group, rearranged Ad/AAV vector genomes (delta Ad/AAV genomes) [38,39], containing solely the 
transgene flanked by AAV-ITRs in an HDAdV genome showed integration at random sites in the host 
genome [38,40]. Other strategies were based on packaging of rAAV genomes into adenoviral capsids 
(AAV/adenovirus hybrid vectors) by including the adenoviral packaging signal in the AAV genome 
[41,42].  
The first Ad/AAV hybrid vector for Rep-mediated site-specific integration at AAVS1 on human 
chromosome 19 was developed by Recchia et al. [31]. This system was based on a two-vector HDAdV 
system. One vector carried the Rep78 gene under control of either the T7 or alpha-1-antitrypsin liver-
specific promoters and the other vector contained an AAV-ITR-flanked transgene. Up to 35% of 
integration events into AAVS1 in HepG2 cells were detected after co-infection with these two 
HDAdVs. However, Rep protein significantly affected the production of the adenovirus encoding the 
elements of the AAV integration machinery [31]. Therefore, further improvements like the Cre/loxP-
expression-switching system to regulate the expression of the rep gene were generated [134]. Later on, 
Recchia and coworkers improved the Ad/AAV hybrid vector by using a tetracycline-regulated rep 
expression system. Notably, in this study the authors could also show site-specific integration into the 
AAVS1 site in AAVS1 transgenic mice and in human primary cells [43].  
To broaden the tropism of adenovirus/AAV hybrid vectors, Gonçalves et al. described the 
generation of dual Ad/AAV hybrid vectors with fiber-modified adenoviral capsids and with all the 
AAV cis- and trans-acting elements needed for locus-specific insertion of exogenous DNA [30]. To 
avoid the well-described interference of the large AAV Rep proteins (i.e., Rep78 and Rep68) on 
adenovirus DNA replication, they devised a flp recombinase-dependent gene switch module to repress 
and activate rep68 expression in producer and target cells, respectively [30]. Studies in HeLa cells 
showed an increased stable transduction level of the transgene and AAVS1-targeted integration of 
vector DNA. Viruses 2009, 1  
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2.2. Adenovirus/Sleeping Beauty transposase hybrid vectors. 
This hybrid vector couples high-efficient gene delivery of HDAdVs with the Sleeping Beauty (SB) 
transposase integration machinery [25]. SB is a synthetic transposable element reconstructed from the 
fish genome and belongs to the Tc1/mariner family of transposable elements. It mediates insertion by a 
‘cut-and-paste’ mechanism into TA sites of the host genome [1]. The transposition process requires the 
binding of the SB-transposase to short direct-repeats embedded in the terminal repeats (IR) flanking 
the transposable elements [1] (Figure 2. iii). Generally, for gene transfer purposes a two-component 
system is used for mobilization of the transposon from the episomal transposon-donor vector. A 
second vector provides the transposable element in trans. Recently, different hyperactive variants of 
SB transposase (SB11 [144],  HSB5 [124], SB100X [48]) were developed by mutational analysis 
screens. Geurts et al. [144] developed the first improved SB transposase (SB11) which enhanced 
transposition efficiencies about threefold [144]. Further improvements of this genetic element for 
somatic integration from Yant and colleagues resulted in the development of the HSB5 transposase 
with 10-fold increased activities compared to the wild type SB transposase [124]. At present the most 
hyperactive transposase (SB100X) displays 100-fold enhanced integration activity [48].  
SB has been shown to provide long-term transgene expression in vitro with a random integration 
profile [44]. In detail, a recent study has shown, in contrast to most retroviral-based vectors that SB 
integrates fairly randomly in mammalian cells with a low preference for actively transcribed genes 
[45]. Besides in vitro studies for transposition, plasmid-based transposons carrying therapeutic 
transgenes were delivered into mice [46,47], transgenic mice were produced and primary 
hematopoietic stem cells were genetically modified [48].  
Since efficient in vivo delivery of the SB transposase system utilizing naked DNA remains a 
challenging task, much effort was spent on designing virus-based delivery technologies. One of the 
first delivery methods was predicated on recombinant adenovirus. Yant and coworkers developed a 
two-component HDAdV-SB transposon system [25]. For the rational design of this hybrid vectors 
system, it has to be mentioned that one precondition for efficient SB-mediated integration is to supply 
a circular substrate [25]. Since adenoviral vector genomes predominantly persist as linear, episomal 
vector genomes, the SB substrate needs to be circularized and therefore mobilized from the adenoviral 
vector genome [7]. In this case, the transposon was achieved by Flp recombination. One vector carried 
a human coagulation factor IX (hFIX) transposon flanked by Flp recombinase recognition target (FRT) 
sites for circularization from the adenoviral vector. The second vector expressed Flp and SB 
transposase. Administration of these vectors resulted in the generation of transposon circles and 
random SB-mediated transposition of the hFIX transgene into the host genome, mediating hFIX 
expression for more than 6 months despite extensive liver regeneration after multiple partial 
hepatectomies [25].  
2.3. Adenovirus/PhiC31 hybrid vectors. 
The integrase from the Streptomyces phage PhiC31 was described in 1991 for the first time [49]. In 
contrast to SB, PhiC31 was shown to mediate an unidirectional site-specific recombination between 
two DNA recognition sequences, the phage attachment site (attP) and the bacterial attachment site 
(attB). Expressed under the control of a mammalian promoter, PhiC31 integrase mediates integration Viruses 2009, 1  
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of extrachromosomal plasmids bearing an attB site into a limited number of ‘pseudo-attP’ sites present 
in native mammalian genomes [2]. A remarkable feature of the PhiC31 integrase for gene therapy is 
the fact that integration is limited to ‘‘hot spot’’ sites with up to 15% specificity in the mammalian 
genome [50-53]. This feature of PhiC31 integrase potentially decreases the risk of insertional 
mutagenesis.  
With respect to integrating viral hybrid vectors, our group utilized HDAdV as an efficient delivery 
vehicle in concert with the integration machinery of integrase PhiC31 for stable transduction and 
limited integration sites [26]. The strategy and the design of this system are schematically displayed in 
Figure 2. iv. Similar to the Ad/SB hybrid, a two-vector system was designed, in which the transgene 
expression cassette is circularized from the HDAdV genome by Flp-mediated recombination, followed 
by PhiC31-mediated somatic integration. This vector system was evaluated in mice and integration of 
the transgene expression cassette from the adenoviral vector resulted in 5-fold higher transgene 
expression levels and integration into the previously described hot spot mpsL1 present in murine liver 
[26,52]. It is of note that recent results may indicate, that Flp-mediated circularization from the linear 
adenoviral vector genome may not even be required for PhiC31 integrase-mediated integration. In 
contrast to the SB transposase integration machinery, linear DNA substrates can serve as substrates for 
PhiC31-mediated integration [26].   
2.4. Adenovirus/retrotransposon hybrid vectors.  
Another strategy for somatic integration of the transgene from an adenoviral vector is the use of 
retrotransposition based on the human long interspersed element-1 (L1). L1 sequences are 
retrotransposons without LTR, which comprise approximately 17% of the human genome. The 
integration mechanism is initiated by L1-RNA expression and its transport into the cytoplasm where 
the ribonucleoprotein particle (RNP) is formed. Subsequently this RNP is transported into the nucleus 
via an unknown mechanism followed by L1-endonuclease mediated cleavage of a consensus target 
DNA in the host genome and subsequent integration. 
The first chimeric system combining HDAdV and L1 retrotransposons has been elaborated by 
Soifer et al. [54]. Efficient adenovirus-mediated delivery of the L1 element into cultured human cells 
resulted in retrotransposition and stable integration of the transgene [24,54] (Figure 2. v). Kubo and 
colleagues developed a second-generation adenovirus-L1 retrotransposon hybrid virus and 
demonstrated, that this L1 element could efficiently retrotranspose in non-dividing cells arrested in the 
G1/S phase of the cell cycle and in differentiated primary human somatic cells [55].  
2.5. Adenovirus/retrovirus hybrid vectors. 
Recently, several research groups designed hybrid vectors that included both retroviral and 
adenoviral elements [27,28,56-58,141-143]. The first reports by Feng et al. [58] and Caplen et al. [56] 
demonstrated the feasibility of this strategy by showing proviral integration in a nude mouse tumor 
model system. The original idea of these approaches was to generate chimeric adenoviral vectors to 
function as transient retroviral producer cells capable of infecting neighbouring cells. Similar to the 
latter approaches, Soifer and colleagues used HDAdV as a carrier to deliver a fully functional 
retrovirus vector [143]. They demonstrated that this HDAdV/RV hybrid vector mediates highly 
efficient gene delivery and permanent integration of transgenes through a two-stage mechanism. With Viruses 2009, 1  
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respect to lentiviral vectors, Kubo and colleagues developed a hybrid vector, in which a HDAdV was 
used as a carrier of the LV production machinery [142]. However, in contrast to the HDAdV/RV 
hybrid vector, the latter vector transduces both dividing and nondividing cells in a TET-inducible 
manner. Furthermore, Kuate et al. [141] took advantage of the high transduction efficiencies of 
adenoviral vectors for generation of a novel packaging system for lentiviral vectors. This system is 
based on transient expression of packaging genes by recombinant adenoviruses. 
The first Ad/RV hybrid vector for somatic integration of a transgene expressing cassette flanked by 
the retroviral long-terminal repeats (LTRs) was generated by Zheng and co-workers [28]. They 
constructed an adenoviral vector (AdLTR–luc) carrying the 5´ and 3´ LTR sequences from murine 
leukemia virus (MLV) and a luciferase reporter gene. Gene expression was observed in cultured cells 
in vitro and in submandibular gland, cortex, and caudate nucleus for as long as three months in vivo. 
The vector integrated randomly into the genome of both dividing and non-dividing cells as determined 
by fluorescence in situ hybridization (10–15% of cells in vitro and 5% in rat spleen in vivo).  
Two years later another Ad/RV hybrid vector was introduced by Murphy et al. [27]. In contrast to 
the earlier study, somatic integration was mediated by retroviral integrase. The strategy was based on 
excision by the Cre recombinase of a provirus circle from the adenoviral vector containing the 
retroviral LTR. In the presence of retroviral Gag and Pol proteins, the excised circle was integrated 
into the host genome by an integrase-directed mechanism. This resulted in a random integration 
process. Both strategies of Ad/RV hybrid vectors (with and without integrase-mediated integration) are 
schematically shown in Figure 2. ii.  
In 2004 an adenovirus/foamy virus (Ad/FV) hybrid vector was developed [59]. For foamy virus 
(FV), a member of the retrovirus family, it is believed that there are no known pathogenicities 
associated with infection. Therefore its integration machinery is attractive for stable gene transfer. The 
Ad/FV hybrid vector, which resulted into 70% of stably transduced cells, contained a complete 
expression cassette for FV gene products (Gag, Pol, and Env) necessary to generate an infectious 
extracellular particle.  
3. HSV-1 based hybrid vectors for somatic integration 
Herpes simplex virus (HSV) belongs to the subfamily of alpha herpesvirus viridae within the family 
of herpesviridae. It is a member of the large group of enveloped viruses and contains a genome of 
approximately 152 kb in size [6]. HSV vectors for gene therapeutic approaches are usually based on 
the HSV serotype 1 (HSV-1). In the clinic HSV-1 typically causes the cold sore, but rarely also acute 
hepatitis, kerato-conjunctivitis or meningo-encephalitis [6]. HSV-1 displays a strong natural tropism 
for neurons and therefore, these vectors were mainly used in gene therapeutic approaches involving the 
nervous system. 
Two fundamentally different HSV-1-based vector systems were developed, recombinant HSV-1 
vectors and HSV-1 amplicons. Whereas recombinant replication-competent HSV-1 vectors are mainly 
used as oncolytic viruses, amplicon vectors with major genome deletions are mainly used as gene 
transfer vectors [60]. 
HSV-1 amplicon vectors are helper-dependent vectors which carry a concatemeric form of a DNA 
plasmid containing for the HSV-1 origin of replication (ori), the HSV-1 packaging signal (pac) and the 
gene of interest. These sequences enable packaging in infectious HSV-1 particle [61]. Herpes virus Viruses 2009, 1  
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amplicon vectors were used as delivery vectors for gene therapy mainly because of their high capacity, 
their low cytotoxicity and the ability of the virions to infected a wide range of dividing and non-diving 
cells, especially neuronal cells [62]. Notably, in contrast to recombinant adenoviral vector genomes, 
the HSV genome circularizes and is maintained within the nucleus as a double-stranded DNA genome. 
Recently, it was shown that these HSV-1 amplicon vectors can be used to deliver DNA constructs that 
are larger than 100 kb [63]. However, the major problem of amplicon vectors is the helper virus free 
production. At present a method combining the total absence of contaminating helper particles with the 
ability to produce very large amounts of amplicon particles is not available [64]. 
Nevertheless, amplicon vectors are used in a large set of experimental applications. However, the 
episomal nature of the HSV-1 amplicon limited the duration of the transgene expression and therefore 
the development of amplicon with the ability to integrate the transgene into the host genome was of 
great interest to research community. The following section will provide an overview of the molecular 
setup of HSV-1 amplicon/AAV hybrid vectors, HSV-1 amplicon/SB transposon hybrid vectors, and 
HSV-1 amplicon/retrovirus hybrid vectors. The basic molecular setup of these hybrid vectors is 
depicted in Figure 3. 
3.1. HSV-1 amplicon/AAV hybrid vectors.  
The first studies incorporated AAV ITRs and Rep functions into HSV-1 amplicon vectors to induce 
integration of the transgene expression cassette into specific sites of host chromosomes as shown in 
Figure 3. ii [65,66]. In initial experiments from Johnston and colleagues an amplicon vector was 
constructed containing the lacZ reporter gene under control of the cytomegalovirus IE1 promoter 
(CMV IE1) flanked by AAV ITR sequences, to facilitate genomic integration of this cassette in the 
host genome [67]. Constructs were generated with and without AAV Rep coding sequences. In the 
presence of Rep proteins transgene retention was supported and after transduction of human glioma 
cells expression for more than two weeks could be detected [67]. Hybrid vector mediated site-specific 
integration in vivo was also provided by Breakefield and colleagues. These authors utilized the HSV-
1/AAV hybrid amplicon vector to successfully target the integration of an ataxia-telangiectasia 
mutated (ATM)-encoding cDNA into the AAVS1 locus of AAVS1-bearing transgenic mice [68].  
Other studies have also shown that hybrid amplicon vectors with transgenes flanked by ITR 
sequences from AAV packaged in HSV-1 virions can mediate integration of transgenes into the 
AAVS1 site in human cells when Rep was provided [65,66,69,70]. However, in these studies 
expression of Rep protein had toxic effects with respect to HSV-1 replication and a low packaging 
efficiency during HSV-1/AAV amplicon production resulting in low titers was observed [65,66].  
To improve the production, Lui et al. added loxP sites into the HSV-1/AAV hybrid amplicon, with 
the intent to excise the ITR-transgene-containing fragment from the amplicon concatemer by   
Cre-loxP-mediated recombination. As a result they yielded titers comparable to those of standard 
HSV-1 amplicons [69]. For small transgene cassettes (4–5 kb) these vectors can achieve genomic 
integration rates of 10–30% of infected human cells in culture with about 50% of these integration 
events occurring specifically at the AAVS1 locus [65,66]. Also large functional inserts of genes   
(100 kb) were successfully integrated into the AAVS1 site using an HSV-1/AAV hybrid vector, but 
efficiency was reduced in comparison to smaller transgene sequences [70].  Viruses 2009, 1  
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Figure 3. Mechanisms of herpes simplex virus 1 (HSV-1) amplicon based integrating 
hybrid vector systems. HSV-1 amplicon systems carry the HSV-1 origin of replication 
(oris), the HSV-1 packaging signal (pac), and the transgene flanked by specific elements 
necessary for the indicated integration machinery. The DNA is packaged as concatemers 
into the HSV-1 virions. (i) For Sleeping Beauty (SB) transposase mediated integration the 
transgene is flanked by inverted repeats (IRs). The SB protein, expressed in trans, binds to 
the IRs excises the transposon and results in reversible random integration in TA-sites in 
the host genome. (ii) The HSV-1/AAV-Rep amplicon hybrid vector leads to site-specific 
insertion of transgenes flanked by AAV inverted terminal repeats (ITR) into the AAVS1 
site of human chromosome 19. The AAV-Rep protein is produced in cis. (iii) In case of 
HSV-1/retrovirus (RV) amplicon vectors the transgene incorporated between two long 
terminal repeats (LTRs) is translocated via the retroviral proteins Gag, Pol and Env. This 
leads to a random integration pattern.  
 
 
3.2. HSV-1 amplicon/SB transposase hybrid vectors.  
A second strategy to induce integration into host chromosomes of transgenes delivered by amplicon 
vectors is the use of DNA transposons like SB transposon (Figure 3. i). This platform consists of two 
vectors, one carrying a viral/cellular promoter driven transgene flanked by SB inverted repeats and the 
second vector harboring the SB transposase gene under the control of the HSV immediate-early 4/5 
gene promoter. Co-delivery of these vectors facilitated long-term expression by random integration in 
vivo and in utero and transmission in dividing cells after integration of the IR flanked transgene into Viruses 2009, 1  
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the mouse genome [71]. In baby hamster kidney (BKH) cells, the authors demonstrated an 
approximately 25-fold increased transduction efficiency using the integration-competent amplicon 
system compared to conventional amplicons.  
3.3. HSV-1 amplicon/retrovirus (RV) hybrid vectors.  
HSV-1/RV hybrid vectors can also provide prolonged transgene expression by integration of the 
transgene into the host genome (Figure 3. iii). Initially, this HSV-1/RV amplicon vector based on 
murine leukemia virus (MLV) was constructed for generation of infectious retroviral particles [72]. In 
addition to the packaging gene and replication origin of HSV-1, this amplicon vector contained MLV 
LTRs flanking the transgene expression cassette and in a separated cassette gag, pol and env proteins 
were encoded [73]. De Felipe et al.  reported the construction of a HSV-1/RV hybrid vector that 
exhibits up to 50-fold higher transgene integration efficiency compared to vectors containing solely 
HSV-1 components [74]. Efficient integration of a retroviral transgene cassette encoding the Pac 
protein in human cells required expression of the MLV gag-pol genes, but in murine cells, also 
endogenous activities could mediate integration, albeit at a lower level. Gene delivery was equally 
efficient in BHK, a cell line resistant to retroviral infection, and in addition transgene retention and 
expression were stable for at least one month in Hs683 human glioma cells.  
4. Retrovirus-based hybrid vectors for somatic integration 
Integrating retroviral vectors have been used for delivery of transgenes for over 20 years of gene 
therapy (Figure 4). Retroviral vectors based on MLV were the first types of vectors used in gene 
transfer and in clinical trials. Today, the list of retroviral vector types for experimental and therapeutic 
applications has been broadly extended. Besides MLV also vectors based on human immunodeficiency 
virus (HIV), avian sarcoma-leukosis virus (ASLV), and foamy virus (FV) are utilized for transduction 
of therapeutic DNA into target cells. Notably, preclinical and clinical gene transfer studies were 
pioneered by MLV-based retroviral vectors in the early nineties. In fact, the first clinical trial in gene 
therapy was performed with retroviral vectors in two girls affected by a form of severe combined 
immune deﬁciency characterized by adenosine deaminase deﬁciency [75]. 
The most desirable advantage of this vector system is the ability of irreversible integration into the 
host genome. For medical application this system introduces a foreign DNA efficiently and easily into 
specific target cells. The molecular organisation of the retroviral genome consists of three open 
reading frames (ORFs) gag, pol and env encoding matrix-, capsid- , envelope proteins, as well as viral 
enzymes like protease, reverse transriptase and the viral integrase. These genes are flanked by long 
terminal repeats (LTRs), responsible i.a. for the regulation of gene expression. The psi element near 
the 5´end of the viral genome encodes the packaging signal for the virus. For complex retroviruses 
additional accessory proteins are synthesized after distinct complex splicing mechanism, which alter 
within the retroviral genus and are essential for viral replication in vivo. For instance HIV-1 generates 
spliced RNA encoding Tat and Rev as well as Vpr, Vif and Nef [76]. 
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Figure 4. Strategies of retroviral integrating hybrid vector systems. Retroviral vector 
systems are (a) based on integrase-expressing retroviruses (RVs) or (b) on integrase-
defective lentiviruses (IDLVs) as transgene delivery machineries. Retroviral RNA, flanked 
by long terminal repeats (LTRs) is reverse transcribed to cDNA by the reverse 
transcriptase (RT) in the host cells. The transgene insertion occurs like indicated in the 
scheme (i-iii). (i) Retroviral vectors express integrase (IN) proteins in cis, which are fused 
to specific DNA-binding domains (DBD) and trigger insertion in specific DBD target sites 
(TS) in the genome. (ii) For site-specific targeting of the transgene, which is delivered by 
IDLVs, zinc-finger nucleases (ZFN) are utilized. The zinc-finger-domain (ZFD) of the 
ZFN binds to the zinc-finger domain target site (ZFD-TS) and mediates double strand 
breaks (DSB) at this specific site in the genome. Subsequently, the transgene is integrated 
and the DNA repaired. (iii) Hybrid vectors based on IDLVs harbour recognition sites 
(inverted repeats, IRs) for Sleeping Beauty (SB) transposase binding. The viral cDNA can 
form a linear structure with 2-LTR motifs or circular formations with 2 LTRs or 1 LTR. 
SB expressed in trans mediates the insertion of the transgene into TA sites of the host 
genome. 
 
 
The mechanism of integration involving participating viral and host proteins is well understood. 
Regarding biosafety in gene therapy, the integration site pattern is a topic of interest. Retroviral 
integrase, which is encoded by the virus, is essential for the transgene insertion process. In concert 
with viral DNA and genomic host DNA, this enzyme builds a preintegration complex (PIC) with the 
LTRs in vivo. The integration process occurs via processing genomic DNA, joining DNA ends and 
postintegration repair of strand breaks [77-81].  
The site selection of integration restricts no specific target sequences in the genome, but it does not 
occur randomly. Within the retroviral family the integration patterns differ significantly [82]. For HIV, 
translocation preferentially occurs into transcriptionally active genes [83]. MLV infections show a 
strong bias towards transcription start sites and CpG islands [84,85]. Also FV and ASLV show a Viruses 2009, 1  
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distinct integration pattern. Regarding FV Trobridge and colleagues revealed that FV did not integrate 
preferentially within genes but with a considerable preference for CpG islands and a low preference 
for integration near transcription start sites [86]. For ASLV it was found that it does neither favour 
integration near transcription start sites, nor does it strongly favour active genes [82,87].  
Because of integration patterns it has been shown that insertion of retroviral DNA can be associated 
with the induction of leukemia in animal models as well as in human therapy trials utilizing MLV 
based vectors for stable gene transfer [88,89]. Therefore, it would be desirable for the usage of 
retrovirus in a gene therapeutic manner, if integrase activity is linked to predetermined and safe 
sequences in the host genome [90]. Herein, we summarize the most important technologies for 
changing the integration profile of retroviral vectors by developing RV-based hybrid vectors. The 
design of these hybrid vectors is displayed schematically in Figure 4. 
4.1. Retrovirus/integrase-fusion protein hybrid vectors. 
Several approaches deal with the construction of integrase (IN) -fusion proteins based on specific 
targeting strategies in the host genome (Figure 4. i). DNA-binding domains (DBD) derived from E. 
coli LexA repressor protein, from the phage λ repressor or a murine transcription factor Zif268 were 
fused either N- or C- terminally to the viral integrase of HIV or ASLV [91-94]. These fusion proteins 
enable site-specific integration nearby their DNA target sites in vitro. More specific targeting into the 
host genome occurs with fusing the integrase to a designed polydactyl zinc-finger motif (E2C) 
enabling the recognition of a specific 18-bp long attachment sequence [95]. These synthetic proteins 
are derived from Cys2-His2 zinc-finger domains and provide site-specific integration in vitro [4]. For 
this E2C/IN-fusion protein it is known that the recognition sequence is located within the 
5´untranslated region of the erb2-gene of the chromosome 17q12 [96]. Incorporation of the IN-E2C 
fusion protein in an infectious virion was performed by providing the protein in trans. Evaluation of 
integration pattern provided a 10-fold higher efficiency regarding the erb2-region compared to the 
wild type virion [4,95,97]. 
4.2. Lentivirus/zinc-finger nuclease hybrid vectors. 
Another strategy for targeting retroviral vectors to specific genome sites is to combine engineered 
zinc-finger nucleases (ZFNs) for site-specific integration and non-integrating lentiviral vectors 
(IDLVs) for delivery (Figure 4. ii). Development of IDLVs is due to the inactivation of the viral 
integrase by mutating the catalytic domain for integration without effecting other protein functions like 
reverse transcriptase activity [98]. During infection IDLVs accumulate episomal intermediates such as 
LTR-circles within a cell and it was shown that these LTR circles mediate short-term transgene 
expression within the transduced cell [99,100].  
Lombardo and colleagues utilized IDLVs to deliver ZFNs for site-specific integration and to 
incorporate template DNA for gene correction into target cells [101]. These ZFN induce double strand 
breaks at the desired DNA sequences, allowing the DNA template to integrate at this particular site 
[102,103]. After binding of the transgene encoding sequence, the DNA break is subsequently repaired 
by the cellular repair mechanism, which involves either non-homologous end joining or homologous 
recombination [104].  Viruses 2009, 1  
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After co-transduction of different cell types with IDLVs containing all elements for ZFN-mediated 
site-specific integration, Lombardo et al. observed that up to 50% of the human stem cells were stably 
transduced [101]. Importantly, these cells showed gene addition at the target sites of the ZFN. This 
method specifies the integration sites by the zinc-finger motifs.  
4.3. Lentivirus/Sleeping Beauty transposase hybrid vectors.  
Very recently, there were two reports utilizing SB transposase in concert with IDLVs [105,106]. 
Both studies took advantage of the IDLV technology for high transduction efficiencies and the SB 
transposase technology for efficient somatic integration of the transgene. After infection with these 
IDLVs, transposition occurs from episomal viral DNA substrates with SB transposase supplied in 
trans (Figure 4. iii). However, the study by Staunstrup and colleagues [105] was based on the newest 
and most hyperactive SB transposase version SB100X and the study by Vink et al. [106] was based on 
the SB transposase mutant SB11 displaying significantly lower integration efficiencies.  
Notably, co-transfected DNA as well as co-transduced IDLVs can serve as the source of active SB 
transposase. In contrast to conventionally used lentiviral vectors, this system resulted into a random 
genomic integration profile and it avoids insertion into active gene regions. These studies showed that 
replacement of the viral integration machinery with non-viral mediators of integration represents a new 
and promising platform of lentiviral vectors with an altered integration profile. 
5. Safety issues 
There are two main starting points for improving the safety of viral hybrid vectors. An optimal 
hybrid vector should account for site-specific integration into a safe locus within the mammalian 
genome without off-target effects and it should result in no or limited immunological responses and 
induce toxic side effects. Therefore, although vectors described in this article have major potential, 
there are also limitations for each single vector system which need to be addressed. The following 
paragraphs will discuss the safety profile of the various vectors presented in this article.  
5.1. Safety and genotoxicity of integration machineries used within hybrid vectors. 
With respect to viral hybrid vectors utilizing SB transposase for somatic integration, one concern 
may be the random integration pattern with approximately 30% integration into actively transcribed 
chromosomal regions [45]. Although SB transposase represents a safer option compared to retroviral 
vectors which predominantly integrate into actively transcribed genes (up to 75% of all integration 
events occur in transcriptionally active genes), it can not be ruled out at present that even a random 
integration pattern may result in genotoxicity. Nevertheless, the SB transposase system holds great 
promises for gene therapy and it did not come as a surprise that in 2008 the first clinical trial was 
initiated. Herein, patients with CD19
+ B-lymphoid malignancies will be treated with genetically 
altered T cells [107] and the SB transposase system will be used to express a CD19-specific chimeric 
antigene receptor in autologous ex vivo expanded T cells. 
Considering the fact that PhiC31 integrase can result in up to 15% specificity of somatic integration 
[50,51], this system also represents an attractive tool for genome engineering and therapeutic 
applications. However, there are important safety issues which need to be addressed before pursuing Viruses 2009, 1  
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this system in preclinical or even clinical studies. One limiting factor is that PhiC31-mediated 
integration preferentially occurs into intron regions of actively transcribed regions [50,51]. Another 
concern is that deletions of DNA at the junctions of chromosomal DNA and the attB attachment sites 
occur. Most importantly, in-depth molecular analyses revealed that chromosomal rearrangements are 
induced as a consequence of PhiC31 activity within treated cells [50,51,69,108]. Our previous study 
revealed that of all analysed integration sites, 15% were found to contain a transgene which was 
flanked by DNA sequences originated from two different chromosomes [51]. Notably, until now 
chromosomal aberrations and deletions were not found after SB- and retrovirus-mediated integration 
of transgenes. Only for recombinant AAV lacking all viral coding sequences (rep and cap) frequent 
chromosomal deletions were detected [36].  
ZFNs for site-specific genomic engineering and gene correction represent one of the most advanced 
technologies. In particular, site-specific integration into a potentially safe harbour of the host genome 
which is not associated with genotoxicity represents a potential solution. However, there is still a risk 
for off-target effects as a consequence of unspecific nuclease activity within transduced cells and there 
is evidence that this in turn may lead to cytotoxicity and apoptosis [109,110]. To address these issues, 
structure-based approaches for improving specificity of ZFNs were performed [111,112]. By 
preventing homodimerization of ZFNs, specificity could be increased and genotoxicity was reduced. 
Nevertheless, as long as off-target effects can not be completely circumvented, this system will require 
improvements. Besides optimizing the structural properties of ZFNs, the actual amount of zinc-finger 
nuclease molecules produced within a cell and the duration of nuclease expression may be an 
important factor influencing safety issues of this technology. 
Besides ZFNs and PhiC31 for site-specific integration, AAV-Rep-protein mediated site-specific 
integration into the human locus AAVS1 on human chromosome 19 (chromosome 19q13.4) seems an 
appealing approach. Having a closer look at the AAVS1 locus and its consequences after AAV 
provirus integration, it was found that amplification and rearrangements at the AAVS1 locus occurred 
due to site-specific provirus integration [113]. Furthermore a number of AAV integration
 hotspots 
were identified
 in the first exon/intron regions of a genomic sequence encoding the p85 protein sharing 
similarity with the myosin binding subunit MBS130 [114]. At present it is not known whether these 
changes on a genomic level can result into any genotoxicity. Previous studies indicated that there is an 
appreciable prevalence of neutralizing antibodies to AAV in the human population (up to 30% for 
AAV2) [115,116], hinting towards noteworthy provirus integration at the AAVS1 site. Thus, one may 
speculate that the probability of unwanted side effects is low, because there is no known pathogenicity 
associated with AAV infection.  
However, there is evidence that Rep-proteins responsible for integration at AAVS1 have negative 
effects on viral replication of HIV, adenovirus and HSV-1[31,65,66,117]. Furthermore, there are hints 
that Rep-proteins, if expressed at high levels, are associated with cytotoxic and/or cytostatic effects 
[118,119]. These are concerns with need to be taken into account when working with this system. 
It remains to be emphasized that with all three systems for targeted integration (ZFNs, phiC31, and 
AAV/Rep) also variable levels of random integration can be observed. Efficiencies of targeted 
integration very from 7% to 90% with various levels of random integration and thus, at present 
genotoxic effects can not be excluded for any of these integration machineries. Viruses 2009, 1  
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Furthermore, it is important to mention that in contrast to naturally integrating vectors such as 
retroviruses, integration frequencies of integrating hybrid vectors may be more difficult to control, 
because these are determined by several factors including cellular entry of two vectors into one cell 
and subsequent chromosomal integration. These features make hybrid vector systems more complex 
and therefore also more unpredictable, which in turn may increase the risk of insertional mutagenesis. 
5.2. Assays to evaluate genotoxicity. 
Last but not least it may be helpful to develop standardized procedures to control reliability and 
safety of each single integrating vector approach. Testing the likelihood of insertional mutagenesis 
may be addressed by performing large-scale sequencing analysis of insertion sites after stable gene 
transfer. This would give us an idea of how many times the therapeutic DNA integrates into 
chromosomal regions with a high risk for genotoxicity. Moreover, it is possible to evaluate the 
oncogenic potential after viral transduction with a recently developed in vitro assay [120] or in a 
tumor-prone mouse model [121].  
5.3. Safety of gene transfer vehicles utilized in the context of hybrid vectors.  
When using viral vectors for gene transfer, it is important to point out that not only genotoxicity but 
also immunological side effects associated with the incoming viral particle itself, the viral proteins 
utilized for somatic integration or with new transgene products that might be recognized as foreign, 
may be a considerable safety concern. Adenovirus vectors are the most immunogenic of all the viral 
vector groups but since the discussion of these unwanted side effects for all viral delivery vehicles 
described in this review would go beyond the scope of this article, please refer to other articles 
specifically dealing with these issues for more detail [135-137].  
Unwanted transduction of non-target cells is another issue of concern. Except for HSV-1, a virus 
which displays a strong neurotropism, retroviral and adenoviral vectors are characterized by a broad 
tropism. Thus, administration of these vectors in vivo may not only result in stable transfection of 
target cells, but also in an “overspill” towards infection of other, unwanted cells.  
It is of note, that the viral- (AAV/Rep, retrovirus integrase) as well the non-viral (SB, Flp, ZFN, 
phiC31) proteins used for integration in the context of hybrid vectors may also cause cellular immune 
responses. However, more in depth studies have to be performed and assays need to be developed to 
address these issues in more detail.  
6. Outlook 
Recapitulating the list of existing viral hybrid vectors described in this review, there are vector-
recombinase-combinations which have not been explored (see also Table 1.). Completing the possible 
combinations by mixing and matching the viral delivery vehicles and the currently established tools for 
somatic integration may be achieved within the next years. But many hurdles remain to overcome. For 
instance rAAV vectors and rAdV for delivery of ZFNs and the respective donor vector providing the 
integration machineries may be an interesting approach to pursue. Also, delivery of SB transposase or 
PhiC31 integrase utilizing AAV vectors may be another alternative to follow. Furthermore, HSV-1 Viruses 2009, 1  
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based therapeutic DNA delivery into neuronal cells may be explored for PhiC31 integrase, but also 
delivery of the ZFN-technology represent an interesting option to look into more closely.  
6.1. Towards a “one-vector system”. 
One important challenge which certainly needs to be addressed in the near future is the complexity 
of currently available hybrid vector systems. The majority of them are based on “two-vector 
strategies”. Disadvantages of these approaches are obvious, because they rely on simultaneous co-
transduction of one cell with two vectors. This experimental setting can be successful for in vitro 
approaches because the viral dose can be increased more easily and the ratio of both vectors can be 
mixed and matched, but for cells with naturally low transduction rates for the respective virus and for 
in vivo approaches this may be problematic with respect to negative side effects.  
We believe that exploring a “one-vector strategy” may be one potential solution. In more detail, this 
means that all components for somatic integration (therapeutic DNA and the respective recombinase) 
are combined in one vector genome. However, as already shown for Ad/AAV hybrid vectors, it may 
be troublesome if the recombinase and the correspondent donor-DNA co-exist in the identical vector 
genome. Expression of the recombinase during vector production may significantly decrease viral 
titers or it may even destroy the vector due to unwanted removing and/or integration of the transgene 
DNA into the host genome of the vector-producer cell line. Thinking about hybrid-vectors utilizing 
AAV as a delivery vehicle, the relatively low packaging capacity of recombinant AAV (4.7 kb) may 
be problematic for insertion of all genetic elements into a single vector. Interestingly, it was suggested 
very recently that AAV serotype 5 (AAV5) capsids may be able to carry a genetic cargo of up to 
8.7 kb [122]. This feature of the AAV5 capsid may be an option for a “single-AAV-vector” approach.  
6.2. Heading for targeted integration.  
One essential improvement required before exploring these hybrid vectors in a clinical setting will 
be the development of recombinases for effective site-specific integration into a safe harbour without 
any side effects. First steps towards this goal have been initiated. For instance ZFNs specifically 
targeting the AAVS1 locus as a potential safe harbour have been generated in collaboration with 
Sangamo BioSciences [123]. In any case, one important question which remains to be answered is 
whether the AAVS1 locus is truly a safe harbour for therapeutic DNA insertion.  
Besides ZFNs for targeted insertion, there have been attempts to generate SB transposase fusion 
proteins for site-specific integration. In that case, specific DNA-binding domains were linked to SB 
transposase redirecting the transposase towards one integration site [124,125]. Although efficiencies of 
these approaches were low, with further improvements this idea may remain a valuable option in view 
of recently generated hyperactive SB variants [48].  
Regarding PhiC31 integrase, there was only one recent report on improving integration efficiencies 
and specificities by performing a mutagenesis screen of the catalytic domain of the PhiC31 protein 
[126]. However, with respect to specificity it may be also interesting to conduct a mutagenesis screen 
of the proposed PhiC31 integrase DNA-binding domain. Furthermore, similar to other approaches 
described above, it may be interesting to develop a PhiC31-zinc-finger fusion protein for redirecting 
target site selection of the PhiC31 protein. Viruses 2009, 1  
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6.3. Surface engineering and retargeting of viral hybrid vectors.  
To essentially broaden applications of adenovirus-, retrovirus-, HSV-1, and AAV-based hybrid 
vectors, it will be of interest to combine these vector types with novel targeting strategies which were 
developed for basically all viral delivery vehicles discussed in this review. For more details about 
targeting strategies for adenoviral, AAV, HSV and retroviral vectors please refer to other review 
articles specifically discussing viral vector targeting and virus tropisms (e.g., [127-132]).  
Last but not least, it is important to explore these hybrid vector systems in larger animals, because 
the toxicity profile may be species dependent. History has taught us that the performance of a viral 
vector strongly differs between mice, larger animals and humans. At present, it remains an unanswered 
question whether combining the best of two worlds in viral hybrid vectors will provide a valuable 
option for therapeutic and experimental gene transfer approaches. Looking into the future, we believe 
that customized viral hybrid vectors which address the single needs of a certain genetic or acquired 
disease will play an important role. 
7. Conclusion 
For successful treatment of various genetic diseases genomic insertion of therapeutic DNA is 
required for achieving long-term therapeutic effects. In this review we provided a state-of-the-art 
overview of integrating hybrid vectors. We believe that these vector types have a high potential for a 
variety of clinical applications for which conventional vectors may not be suited, because hybrid 
vectors may be specifically designed for a certain disease and its individual needs. However, at the 
time the appropriate answer to the original question raised in the title of this review article (Viral 
hybrid vectors for somatic integration - are they really the better solution?) should be that for certain 
diseases and applications the current versions of integrating viral hybrid may be the better solution but 
for others they are not. 
For instance, due to the complexity of currently available hybrid vector systems, they may not be 
suited for in vivo applications in their current forms. We believe that gene therapy of monogenic 
diseases like hemophilia B would most likely not benefit from integrating viral hybrid vectors, because 
non-integrating HDAdV and AAV vectors were already shown to result in long-term expression of the 
human coagulation factor IX in mice and dogs [23,146]. Furthermore, it remains to be seen whether 
integrating hybrid vectors that are based on SB transposases, ZFNs or other integrases will indeed 
show safer integration profiles and less side-effects in a clinical setting, compared to currently used 
and improved versions of MLV and HIV-based vectors. 
However, we think that integrating viral hybrid vectors will be beneficial for the treatment of some 
diseases originated from rapidly dividing cells like stem cells, keratinocytes or cancer cells. Within 
these large groups of target cells, hybrid vectors may find an important niche for transduction of those 
cell types for which MLV and HIV-based are not suited. Furthermore, conventionally used integrating 
vectors are limited by their packaging capacity. For example retroviral and lentiviral vectors have a 
limiting packaging capacity of 8-10 kb. Therefore, the significantly higher packaging capacity of 
HDAdV- and HSV-based hybrid vectors will be the only solution for diseases which require stable 
transduction of cells with large transgenes (> 10 kb).  Viruses 2009, 1  
 
1315
Acknowledgements 
This work was supported by DFG grants SPP1230 and SFB 455, EU grant FP7 (PERSIST), and the 
Wilhelm Sander Foundation to A.E.  
References and Notes 
1.  Ivics, Z.; Hackett, P.B.; Plasterk, R.H.; Izsvak, Z. Molecular reconstruction of Sleeping Beauty, a 
Tc1-like transposon from fish, and its transposition in human cells. Cell 1997, 91, 501-510. 
2.  Groth, A.C.; Olivares, E.C.; Thyagarajan, B.; Calos, M.P. A phage integrase directs efficient site-
specific integration in human cells. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 5995-6000. 
3.  Groth, A.C.; Calos, M.P. Phage integrases: biology and applications. J. Mol. Biol. 2004, 335,  
667-678. 
4.  Beerli, R.R.; Barbas, C.F., III. Engineering polydactyl zinc-finger transcription factors. Nat. 
Biotechnol. 2002, 20, 135-141. 
5.  Carroll, D. Progress and prospects: zinc-finger nucleases as gene therapy agents. Gene Ther. 
2008, 15, 1463-1468. 
6.  Knipe, D.M. and Howley P.M. Fields Virology, 5th ed.; Lippincott Williams & Wilkins: 
Philadelphia, PA, USA, 2006.  
7.  Jager, L.; Ehrhardt, A. Persistence of high-capacity adenoviral vectors as replication-defective 
monomeric genomes in vitro and in murine liver. Hum. Gene Ther. 2009, 20, 883-896. 
8.  Stephen, S.L.; Sivanandam, V.G.; Kochanek, S. Homologous and heterologous recombination 
between adenovirus vector DNA and chromosomal DNA. J. Gene Med. 2008, 10, 1176-1189. 
9.  Stabel, S.; Doerfler, W.; Friis, R.R. Integration sites of adenovirus type 12 DNA in transformed 
hamster cells and hamster tumor cells. J. Virol. 1980, 36, 22-40. 
10  Sutter, D.; Westphal, M.; Doerfler, W. Patterns of integration of viral DNA sequences in the 
genomes of adenovirus type 12-transformed hamster cells. Cell 1978, 14, 569-585. 
11  Vogel, S.; Rosahl, T.; Doerfler, W. Chromosomal localization of integrated adenovirus DNA in 
productively infected and in transformed mammalian cells. Virology 1986, 152, 159-170. 
12. Edelstein, M.L.; Abedi, M.R.; Wixon, J. Gene therapy clinical trials worldwide to 2007--an 
update. J. Gene Med. 2007, 9, 833-842. 
13. Benihoud, K.; Yeh, P.; Perricaudet, M. Adenovirus vectors for gene delivery. Curr. Opin. 
Biotechnol. 1999, 10, 440-447. 
14. Andrews, J.L.; Kadan, M.J.; Gorziglia, M.I.; Kaleko, M.; Connelly, S. Generation and 
characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII. Mol. 
Ther. 2001, 3, 329-336. 
15.  Lusky, M.; Christ, M.; Rittner, K.; Dieterle, A.; Dreyer, D.; Mourot, B.; Schultz, H.; Stoeckel, F.; 
Pavirani, A.; Mehtali, M. In vitro and in vivo biology of recombinant adenovirus vectors with E1, 
E1/E2A, or E1/E4 deleted. J. Virol. 1998, 72, 2022-2032. 
16. Yang, Y.; Ertl, H.C.; Wilson, J.M. MHC class I-restricted cytotoxic T lymphocytes to viral 
antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. 
Immunity 1994, 1, 433-442. Viruses 2009, 1  
 
1316
17. Ehrhardt, A.; Kay, M.A. A new adenoviral helper-dependent vector results in long-term 
therapeutic levels of human coagulation factor IX at low doses in vivo.  Blood  2002,  99,  
3923-3930. 
18.  Parks, R.J.; Chen, L.; Anton, M.; Sankar, U.; Rudnicki, M.A.; Graham, F.L. A helper-dependent 
adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral 
packaging signal. Proc. Natl. Acad. Sci. U. S. A 1996, 93, 13565-13570. 
19.  McCaffrey, A.P.; Fawcett, P.; Nakai, H.; McCaffrey, R.L.; Ehrhardt, A.; Pham, T.T.; Pandey, K.; 
Xu, H.; Feuss, S.; Storm, T.A.; Kay, M.A. The host response to adenovirus, helper-dependent 
adenovirus, and adeno-associated virus in mouse liver. Mol. Ther. 2008, 16, 931-941. 
20.  Schiedner, G.; Hertel, S.; Johnston, M.; Biermann, V.; Dries, V.; Kochanek, S. Variables affecting 
in vivo performance of high-capacity adenovirus vectors. J. Virol. 2002, 76, 1600-1609. 
21.  Brunetti-Pierri, N.; Grove, N.C.; Zuo, Y.; Edwards, R.; Palmer, D.; Cerullo, V.; Teruya, J.; Ng, P. 
Bioengineered Factor IX Molecules with Increased Catalytic Activity Improve the Therapeutic 
Index of Gene Therapy Vectors for Hemophilia B. Hum. Gene Ther. 2009, 20, 479-85. 
22.  Barr, D.; Tubb, J.; Ferguson, D.; Scaria, A.; Lieber, A.; Wilson, C.; Perkins, J.; Kay, M.A. Strain 
related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: 
comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther. 1995, 2, 
151-155. 
23.  Ehrhardt, A.; Xu, H.; Kay, M.A. Episomal persistence of recombinant adenoviral vector genomes 
during the cell cycle in vivo. J. Virol. 2003, 77, 7689-7695. 
24. Soifer, H.S.; Kasahara, N. Retrotransposon-adenovirus hybrid vectors: efficient delivery and 
stable integration of transgenes via a two-stage mechanism. Curr. Gene Ther. 2004, 4, 373-384. 
25.  Yant, S.R.; Ehrhardt, A.; Mikkelsen, J.G.; Meuse, L.; Pham, T.; Kay, M.A. Transposition from a 
gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat. Biotechnol. 2002, 20, 
999-1005. 
26.  Ehrhardt, A.; Yant, S.R.; Giering, J.C.; Xu, H.; Engler, J.A.; Kay, M.A. Somatic integration from 
an adenoviral hybrid vector into a hot spot in mouse liver results in persistent transgene 
expression levels in vivo. Mol. Ther. 2007, 15, 146-156. 
27.  Murphy, S.J.; Chong, H.; Bell, S.; Diaz, R.M.; Vile, R.G. Novel integrating adenoviral/retroviral 
hybrid vector for gene therapy. Hum. Gene Ther. 2002, 13, 745-760. 
28.  Zheng, C.; Baum, B.J.; Iadarola, M.J.; O'Connell, B.C. Genomic integration and gene expression 
by a modified adenoviral vector. Nat. Biotechnol. 2000, 18, 176-180. 
29.  Goncalves, M.A.; Holkers, M.; Cudre-Mauroux, C.; van Nierop, G.P.; Knaan-Shanzer, S.; van, d. 
V., I; Valerio, D.; de Vries, A.A. Transduction of myogenic cells by retargeted dual high-capacity 
hybrid viral vectors: robust dystrophin synthesis in duchenne muscular dystrophy muscle cells. 
Mol. Ther. 2006, 13, 976-986. 
30. Goncalves, M.A.; Holkers, M.; van Nierop, G.P.; Wieringa, R.; Pau, M.G.; de Vries, A.A. 
Targeted chromosomal insertion of large DNA into the human genome by a fiber-modified high-
capacity adenovirus-based vector system. PLoS One 2008, 3, e3084. 
31. Recchia, A.; Parks, R.J.; Lamartina, S.; Toniatti, C.; Pieroni, L.; Palombo, F.; Ciliberto, G.; 
Graham, F.L.; Cortese, R.; La, M.N.; Colloca, S. Site-specific integration mediated by a hybrid 
adenovirus/adeno-associated virus vector. Proc. Natl. Acad. Sci. U. S. A 1999, 96, 2615-2620. Viruses 2009, 1  
 
1317
32.  Fisher, K.J.; Kelley, W.M.; Burda, J.F.; Wilson, J.M. A novel adenovirus-adeno-associated virus 
hybrid vector that displays efficient rescue and delivery of the AAV genome. Hum. Gene Ther. 
1996, 7, 2079-2087. 
33.  Kotin, R.M.; Siniscalco, M.; Samulski, R.J.; Zhu, X.D.; Hunter, L.; Laughlin, C.A.; McLaughlin, 
S.; Muzyczka, N.; Rocchi, M.; Berns, K.I. Site-specific integration by adeno-associated virus. 
Proc. Natl. Acad. Sci. U. S. A. 1990, 87, 2211-2215. 
34.  Linden, R.M.; Ward, P.; Giraud, C.; Winocour, E.; Berns, K.I. Site-specific integration by adeno-
associated virus. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 11288-11294. 
35. Samulski, R.J.; Zhu, X.; Xiao, X.; Brook, J.D.; Housman, D.E.; Epstein, N.; Hunter, L.A. 
Targeted integration of adeno-associated virus(AAV) into human chromosome 19. EMBO J. 
1991, 10, 3941-3950. 
36.  Nakai, H.; Montini, E.; Fuess, S.; Storm, T.A.; Grompe, M.; Kay, M.A. AAV serotype 2 vectors 
preferentially integrate into active genes in mice. Nat. Genet. 2003, 34, 297-302. 
37.  Nakai, H.; Thomas, C.E.; Storm, T.A.; Fuess, S.; Powell, S.; Wright, J.F.; Kay, M.A. A limited 
number of transducible hepatocytes restricts a wide-range linear vector dose response in 
recombinant adeno-associated virus-mediated liver transduction. J. Virol. 2002, 76, 11343-11349. 
38.  Lieber, A.; Steinwaerder, D.S.; Carlson, C.A.; Kay, M.A. Integrating adenovirus-adeno-associated 
virus hybrid vectors devoid of all viral genes. J. Virol. 1999, 73, 9314-9324. 
39. Sandalon, Z.; Gnatenko, D.V.; Bahou, W.F.; Hearing, P. Adeno-associated virus(AAV) Rep 
protein enhances the generation of a recombinant mini-adenovirus(Ad) utilizing an Ad/AAV 
hybrid virus. J. Virol. 2000, 74, 10381-10389. 
40.  Shayakhmetov, D.M.; Carlson, C.A.; Stecher, H.; Li, Q.; Stamatoyannopoulos, G.; Lieber, A. A 
high-capacity, capsid-modified hybrid adenovirus/adeno-associated virus vector for stable 
transduction of human hematopoietic cells. J. Virol. 2002, 76, 1135-1143. 
41.  Goncalves, M.A.; Pau, M.G.; de Vries, A.A.; Valerio, D. Generation of a high-capacity hybrid 
vector: packaging of recombinant adenoassociated virus replicative intermediates in adenovirus 
capsids overcomes the limited cloning capacity of adenoassociated virus vectors. Virology 2001, 
288, 236-246. 
42.  Goncalves, M.A.; van, d. V., I; Janssen, J.M.; Maassen, B.T.; Heemskerk, E.H.; Opstelten, D.J.; 
Knaan-Shanzer, S.; Valerio, D.; de Vries, A.A. Efficient generation and amplification of high-
capacity adeno-associated virus/adenovirus hybrid vectors. J. Virol. 2002, 76, 10734-10744. 
43.  Recchia, A.; Perani, L.; Sartori, D.; Olgiati, C.; Mavilio, F. Site-specific integration of functional 
transgenes into the human genome by adeno/AAV hybrid vectors. Mol. Ther. 2004, 10, 660-670. 
44.  Ivics, Z.; Izsvak, Z. Transposons for gene therapy! Curr. Gene Ther. 2006, 6, 593-607. 
45.  Yant, S.R.; Wu, X.; Huang, Y.; Garrison, B.; Burgess, S.M.; Kay, M.A. High-resolution genome-
wide mapping of transposon integration in mammals. Mol. Cell Biol. 2005, 25, 2085-2094. 
46. Mikkelsen, J.G.; Yant, S.R.; Meuse, L.; Huang, Z.; Xu, H.; Kay, M.A. Helper-Independent 
Sleeping Beauty transposon-transposase vectors for efficient nonviral gene delivery and persistent 
gene expression in vivo. Mol. Ther. 2003, 8, 654-665. 
47.  Yant, S.R.; Meuse, L.; Chiu, W.; Ivics, Z.; Izsvak, Z.; Kay, M.A. Somatic integration and long-
term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat. 
Genet. 2000, 25, 35-41. Viruses 2009, 1  
 
1318
48.  Mates, L.; Chuah, M.K.; Belay, E.; Jerchow, B.; Manoj, N.; costa-Sanchez, A.; Grzela, D.P.; 
Schmitt, A.; Becker, K.; Matrai, J.; Ma, L.; Samara-Kuko, E.; Gysemans, C.; Pryputniewicz, D.; 
Miskey, C.; Fletcher, B.; Vandendriessche, T.; Ivics, Z.; Izsvak, Z. Molecular evolution of a novel 
hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat. 
Genet. 2009, 41, 753-761. 
49.  Kuhstoss, S.; Rao, R.N. Analysis of the integration function of the streptomycete bacteriophage 
phi C31. J. Mol. Biol. 1991, 222, 897-908. 
50. Chalberg, T.W.; Portlock, J.L.; Olivares, E.C.; Thyagarajan, B.; Kirby, P.J.; Hillman, R.T.; 
Hoelters, J.; Calos, M.P. Integration specificity of phage PhiC31 integrase in the human genome. 
J Mol. Biol. 2006, 357, 28-48. 
51.  Ehrhardt, A.; Engler, J.A.; Xu, H.; Cherry, A.M.; Kay, M.A. Molecular analysis of chromosomal 
rearrangements in mammalian cells after PhiC31-mediated integration. Hum. Gene Ther. 2006, 
17, 1077-1094. 
52.  Olivares, E.C.; Hollis, R.P.; Chalberg, T.W.; Meuse, L.; Kay, M.A.; Calos, M.P. Site-specific 
genomic integration produces therapeutic Factor IX levels in mice. Nat. Biotechnol. 2002, 20, 
1124-1128. 
53.  Thyagarajan, B.; Olivares, E.C.; Hollis, R.P.; Ginsburg, D.S.; Calos, M.P. Site-specific genomic 
integration in mammalian cells mediated by phage PhiC31 integrase. Mol. Cell Biol. 2001, 21, 
3926-3934. 
54.  Soifer, H.; Higo, C.; Kazazian, H.H., Jr.; Moran, J.V.; Mitani, K.; Kasahara, N. Stable integration 
of transgenes delivered by a retrotransposon-adenovirus hybrid vector. Hum. Gene Ther. 2001, 
12, 1417-1428. 
55.  Kubo, S.; Seleme, M.C.; Soifer, H.S.; Perez, J.L.; Moran, J.V.; Kazazian, H.H., Jr.; Kasahara, N. 
L1 retrotransposition in nondividing and primary human somatic cells. Proc. Natl. Acad. Sci.  
U. S. A 2006, 103, 8036-8041. 
56.  Caplen, N.J.; Higginbotham, J.N.; Scheel, J.R.; Vahanian, N.; Yoshida, Y.; Hamada, H.; Blaese, 
R.M.; Ramsey, W.J. Adeno-retroviral chimeric viruses as in vivo transducing agents. Gene Ther. 
1999, 6, 454-459. 
57.  Duisit, G.; Salvetti, A.; Moullier, P.; Cosset, F.L. Functional characterization of 
adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer 
cell lines. Hum. Gene Ther. 1999, 10, 189-200. 
58.  Feng, M.; Jackson, W.H., Jr.; Goldman, C.K.; Rancourt, C.; Wang, M.; Dusing, S.K.; Siegal, G.; 
Curiel, D.T. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. 
Nat. Biotechnol. 1997, 15, 866-870. 
59.  Picard-Maureau, M.; Kreppel, F.; Lindemann, D.; Juretzek, T.; Herchenroder, O.; Rethwilm, A.; 
Kochanek, S.; Heinkelein, M. Foamy virus--adenovirus hybrid vectors. Gene Ther. 2004, 11,  
722-728. 
60.  Nawa, A.; Luo, C.; Zhang, L.; Ushjima, Y.; Ishida, D.; Kamakura, M.; Fujimoto, Y.; Goshima, F.; 
Kikkawa, F.; Nishiyama, Y. Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-
10: applications for cancer gene therapy. Curr. Gene Ther. 2008, 8, 208-221. 
61.  Spaete, R.R.; Frenkel, N. The herpes simplex virus amplicon: a new eucaryotic defective-virus 
cloning-amplifying vector. Cell 1982, 30, 295-304. Viruses 2009, 1  
 
1319
62.  Sena-Esteves, M.; Saeki, Y.; Fraefel, C.; Breakefield, X.O. HSV-1 amplicon vectors--simplicity 
and versatility. Mol. Ther. 2000, 2, 9-15. 
63.  Wade-Martins, R.; Smith, E.R.; Tyminski, E.; Chiocca, E.A.; Saeki, Y. An infectious transfer and 
expression system for genomic DNA loci in human and mouse cells. Nat. Biotechnol. 2001, 19, 
1067-1070. 
64.  Epstein, A.L. HSV-1-derived amplicon vectors: recent technological improvements and remaining 
difficulties--a review. Mem. Inst. Oswaldo Cruz 2009, 104, 399-410. 
65.  Heister, T.; Heid, I.; Ackermann, M.; Fraefel, C. Herpes simplex virus type 1/adeno-associated 
virus hybrid vectors mediate site-specific integration at the adeno-associated virus preintegration 
site, AAVS1, on human chromosome 19. J. Virol. 2002, 76, 7163-7173. 
66.  Wang, Y.; Camp, S.M.; Niwano, M.; Shen, X.; Bakowska, J.C.; Breakefield, X.O.; Allen, P.D. 
Herpes simplex virus type 1/adeno-associated virus rep(+) hybrid amplicon vector improves the 
stability of transgene expression in human cells by site-specific integration. J. Virol. 2002, 76, 
7150-7162. 
67.  Johnston, K.M.; Jacoby, D.; Pechan, P.A.; Fraefel, C.; Borghesani, P.; Schuback, D.; Dunn, R.J.; 
Smith, F.I.; Breakefield, X.O. HSV/AAV hybrid amplicon vectors extend transgene expression in 
human glioma cells. Hum. Gene Ther. 1997, 8, 359-370. 
68.  Cortes, M.L.; Oehmig, A.; Saydam, O.; Sanford, J.D.; Perry, K.F.; Fraefel, C.; Breakefield, X.O. 
Targeted integration of functional human ATM cDNA into genome mediated by HSV/AAV 
hybrid amplicon vector. Mol. Ther. 2008, 16, 81-88. 
69.  Liu, J.; Jeppesen, I.; Nielsen, K.; Jensen, T.G. Phi c31 integrase induces chromosomal aberrations 
in primary human fibroblasts. Gene Ther. 2006, 13, 1188-1190. 
70. Oehmig, A.; Cortes, M.L.; Perry, K.F.; Sena-Esteves, M.; Fraefel, C.; Breakefield, X.O. 
Integration of active human beta-galactosidase gene (100 kb) into genome using HSV/AAV 
amplicon vector. Gene Ther. 2007, 14, 1078-1091. 
71.   Bowers, W.J.; Mastrangelo, M.A.; Howard, D.F.; Southerland, H.A.; Maguire-Zeiss, K.A.; 
Federoff, H.J. Neuronal precursor-restricted transduction via in utero CNS gene delivery of a 
novel bipartite HSV amplicon/transposase hybrid vector. Mol. Ther. 2006, 13, 580-588. 
72.  Savard, N.; Cosset, F.L.; Epstein, A.L. Defective herpes simplex virus type 1 vectors harboring 
gag, pol, and env genes can be used to rescue defective retrovirus vectors. J. Virol. 1997, 71, 
4111-4117. 
73.    Sena-Esteves, M.; Saeki, Y.; Camp, S.M.; Chiocca, E.A.; Breakefield, X.O. Single-step 
conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus 
hybrid amplicons. J. Virol. 1999, 73, 10426-10439. 
74.  de Felipe, P.; Izquierdo, M.; Wandosell, F.; Lim, F. Integrating retroviral cassette extends gene 
delivery of HSV-1 expression vectors to dividing cells. Biotechniques 2001, 31, 394-395. 
75.  Blaese, R.M.; Culver, K.W.; Miller, A.D.; Carter, C.S.; Fleisher, T.; Clerici, M.; Shearer, G.; 
Chang, L.; Chiang, Y.; Tolstoshev, P.; Greenblatt, J.J.; Rosenberg, S.A.; Klein, H.; Berger, M.; 
Mullen, C.A.; Ramsey, W.J.; Muul, L.; Morgan, R.A.; Anderson, W.F. T lymphocyte-directed 
gene therapy for ADA- SCID: initial trial results after 4 years. Science 1995, 270, 475-480. 
76.  Arrigo, S.J.; Weitsman, S.; Zack, J.A.; Chen, I.S. Characterization and expression of novel singly 
spliced RNA species of human immunodeficiency virus type 1. J. Virol. 1990, 64, 4585-4588. Viruses 2009, 1  
 
1320
77.   Coffin, J.M. Structure, replication, and recombination of retrovirus genomes: some unifying 
hypotheses. J. Gen. Virol. 1979, 42, 1-26. 
78.  Coffin, J.M. Retroviral DNA integration. Dev. Biol. Stand. 1992, 76, 141-151. 
79.  Daniel, R.; Katz, R.A.; Skalka, A.M. A role for DNA-PK in retroviral DNA integration. Science 
1999, 284, 644-647. 
80.  Skalka, A.M.; Katz, R.A. Retroviral DNA integration and the DNA damage response. Cell Death 
Differ. 2005, 12, 971-978. 
81.  Smith, J.A.; Daniel, R. Following the path of the virus: the exploitation of host DNA repair 
mechanisms by retroviruses. ACS Chem. Biol. 2006, 1, 217-226. 
82.   Mitchell, R.S.; Beitzel, B.F.; Schroder, A.R.; Shinn, P.; Chen, H.; Berry, C.C.; Ecker, J.R.; 
Bushman, F.D. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site 
preferences. PLoS. Biol. 2004, 2, E234. 
83.  Schroder, A.R.; Shinn, P.; Chen, H.; Berry, C.; Ecker, J.R.; Bushman, F. HIV-1 integration in the 
human genome favors active genes and local hotspots. Cell 2002, 110, 521-529. 
84.  Lewinski, M.K.; Yamashita, M.; Emerman, M.; Ciuffi, A.; Marshall, H.; Crawford, G.; Collins, 
F.; Shinn, P.; Leipzig, J.; Hannenhalli, S.; Berry, C.C.; Ecker, J.R.; Bushman, F.D. Retroviral 
DNA integration: viral and cellular determinants of target-site selection. PLoS. Pathog. 2006, 2, 
e60. 
85.  Wu, X.; Li, Y.; Crise, B.; Burgess, S.M. Transcription start regions in the human genome are 
favored targets for MLV integration. Science 2003, 300, 1749-1751. 
86.  Trobridge, G.D.; Miller, D.G.; Jacobs, M.A.; Allen, J.M.; Kiem, H.P.; Kaul, R.; Russell, D.W. 
Foamy virus vector integration sites in normal human cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 
103, 1498-1503. 
87.  Derse, D.; Crise, B.; Li, Y.; Princler, G.; Lum, N.; Stewart, C.; McGrath, C.F.; Hughes, S.H.; 
Munroe, D.J.; Wu, X. Human T-cell leukemia virus type 1 integration target sites in the human 
genome: comparison with those of other retroviruses. J. Virol. 2007, 81, 6731-6741. 
88.  Hacein-Bey-Abina, S.; Von, K.C.; Schmidt, M.; McCormack, M.P.; Wulffraat, N.; Leboulch, P.; 
Lim, A.; Osborne, C.S.; Pawliuk, R.; Morillon, E.; Sorensen, R.; Forster, A.; Fraser, P.; Cohen, J. 
I.; de Saint, B.G.; Alexander, I.; Wintergerst, U.; Frebourg, T.; Aurias, A.; Stoppa-Lyonnet, D.; 
Romana, S.; Radford-Weiss, I.; Gross, F.; Valensi, F.; Delabesse, E.; Macintyre, E.; Sigaux, F.; 
Soulier, J.; Leiva, L.E.; Wissler, M.; Prinz, C.; Rabbitts, T.H.; Le, D.F.; Fischer, A.; Cavazzana-
Calvo, M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for 
SCID-X1. Science 2003, 302, 415-419. 
89.  Li, Z.; Dullmann, J.; Schiedlmeier, B.; Schmidt, M.; Von, K.C.; Meyer, J.; Forster, M.; Stocking, 
C.; Wahlers, A.; Frank, O.; Ostertag, W.; Kuhlcke, K.; Eckert, H.G.; Fehse, B.; Baum, C. Murine 
leukemia induced by retroviral gene marking. Science 2002, 296, 497. 
90.   Tomanin, R.; Scarpa, M. Why do we need new gene therapy viral vectors? Characteristics, 
limitations and future perspectives of viral vector transduction. Curr. Gene Ther.  2004,  4,  
357-372. 
91.   Bushman, F.D. Tethering human immunodeficiency virus 1 integrase to a DNA site directs 
integration to nearby sequences. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 9233-9237. Viruses 2009, 1  
 
1321
92.   Bushman, F.D.; Miller, M.D. Tethering human immunodeficiency virus type 1 preintegration 
complexes to target DNA promotes integration at nearby sites. J. Virol. 1997, 71, 458-464. 
93.   Goulaouic, H.; Chow, S.A. Directed integration of viral DNA mediated by fusion proteins 
consisting of human immunodeficiency virus type 1 integrase and Escherichia coli LexA protein. 
J. Virol. 1996, 70, 37-46. 
94.  Katz, R.A.; Merkel, G.; Skalka, A.M. Targeting of retroviral integrase by fusion to a heterologous 
DNA binding domain: in vitro activities and incorporation of a fusion protein into viral particles. 
Virology 1996, 217, 178-190. 
95.  Tan, W.; Dong, Z.; Wilkinson, T.A.; Barbas, C.F., III; Chow, S.A. Human immunodeficiency 
virus type 1 incorporated with fusion proteins consisting of integrase and the designed polydactyl 
zinc finger protein E2C can bias integration of viral DNA into a predetermined chromosomal 
region in human cells. J. Virol. 2006, 80, 1939-1948. 
96.  Beerli, R.R.; Segal, D.J.; Dreier, B.; Barbas, C.F., III. Toward controlling gene expression at will: 
specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins 
constructed from modular building blocks. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 14628-14633. 
97.  Beerli, R.R.; Dreier, B.; Barbas, C.F., III. Positive and negative regulation of endogenous genes 
by designed transcription factors. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 1495-1500. 
98.  Vargas, J., Jr.; Gusella, G.L.; Najfeld, V.; Klotman, M.E.; Cara, A. Novel integrase-defective 
lentiviral episomal vectors for gene transfer. Hum. Gene Ther. 2004, 15, 361-372. 
99.    Moldt, B.; Staunstrup, N.H.; Jakobsen, M.; Yanez-Munoz, R.J.; Mikkelsen, J.G. Genomic 
insertion of lentiviral DNA circles directed by the yeast Flp recombinase. BMC. Biotechnol. 2008, 
8, 60. 
100.Nightingale, S.J.; Hollis, R.P.; Pepper, K.A.; Petersen, D.; Yu, X.J.; Yang, C.; Bahner, I.; Kohn, 
D.B. Transient gene expression by nonintegrating lentiviral vectors. Mol. Ther.  2006,  13,  
1121-1132. 
101.  Lombardo, A.; Genovese, P.; Beausejour, C.M.; Colleoni, S.; Lee, Y.L.; Kim, K.A.; Ando, D.; 
Urnov, F.D.; Galli, C.; Gregory, P.D.; Holmes, M.C.; Naldini, L. Gene editing in human stem 
cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat. 
Biotechnol. 2007, 25, 1298-1306. 
102. Bitinaite, J.; Wah, D.A.; Aggarwal, A.K.; Schildkraut, I. FokI dimerization is required for DNA 
cleavage. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 10570-10575. 
103.Cornu, T.I.; Thibodeau-Beganny, S.; Guhl, E.; Alwin, S.; Eichtinger, M.; Joung, J.K.; Cathomen, 
T. DNA-binding specificity is a major determinant of the activity and toxicity of zinc-finger 
nucleases. Mol. Ther. 2008, 16, 352-358. 
104. Cahill, D.; Connor, B.; Carney, J.P. Mechanisms of eukaryotic DNA double strand break repair. 
Front Biosci. 2006, 11, 1958-1976. 
105.  Staunstrup, N.H.; Moldt, B.; Mates, L.; Villesen, P.; Jakobsen, M.; Ivics, Z.; Izsvak, Z.; 
Mikkelsen, J.G. Hybrid lentivirus-transposon vectors with a random integration profile in human 
cells. Mol. Ther. 2009, 17, 1205-1214. 
106.  Vink, C.A.; Gaspar, H.B.; Gabriel, R.; Schmidt, M.; McIvor, R.S.; Thrasher, A.J.; Qasim, W. 
Sleeping beauty transposition from nonintegrating lentivirus. Mol. Ther. 2009, 17, 1197-1204. Viruses 2009, 1  
 
1322
107.Williams, D.A. Sleeping beauty vector system moves toward human trials in the United States. 
Mol. Ther. 2008, 16, 1515-1516. 
108.Liu, J.; Skjorringe, T.; Gjetting, T.; Jensen, T.G. PhiC31 integrase induces a DNA damage 
response and chromosomal rearrangements in human adult fibroblasts. BMC. Biotechnol. 2009, 9, 
31. 
109.Alwin, S.; Gere, M.B.; Guhl, E.; Effertz, K.; Barbas, C.F., III; Segal, D.J.; Weitzman, M.D.; 
Cathomen, T. Custom zinc-finger nucleases for use in human cells. Mol. Ther. 2005, 12, 610-617. 
110.Porteus, M.H.; Baltimore, D. Chimeric nucleases stimulate gene targeting in human cells. Science 
2003, 300, 763. 
111.  Miller, J.C.; Holmes, M.C.; Wang, J.; Guschin, D.Y.; Lee, Y.L.; Rupniewski, I.; Beausejour, 
C.M.; Waite, A.J.; Wang, N.S.; Kim, K.A.; Gregory, P.D.; Pabo, C.O.; Rebar, E.J. An improved 
zinc-finger nuclease architecture for highly specific genome editing. Nat. Biotechnol. 2007, 25, 
778-785. 
112.  Szczepek, M.; Brondani, V.; Buchel, J.; Serrano, L.; Segal, D.J.; Cathomen, T. Structure-based 
redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases. Nat. 
Biotechnol. 2007, 25, 786-793. 
113.  Hamilton, H.; Gomos, J.; Berns, K.I.; Falck-Pedersen, E. Adeno-associated virus site-specific 
integration and AAVS1 disruption. J. Virol. 2004, 78, 7874-7882. 
114.  Tan, I.; Ng, C.H.; Lim, L.; Leung, T. Phosphorylation of a novel myosin binding subunit of 
protein phosphatase 1 reveals a conserved mechanism in the regulation of actin cytoskeleton.  
J. Biol. Chem. 2001, 276, 21209-21216. 
115.  Calcedo, R.; Vandenberghe, L.H.; Gao, G.; Lin, J.; Wilson, J.M. Worldwide epidemiology of 
neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 2009, 199, 381-390. 
116. Halbert, C.L.; Miller, A.D.; McNamara, S.; Emerson, J.; Gibson, R.L.; Ramsey, B.; Aitken, M.L. 
Prevalence of neutralizing antibodies against adeno-associated virus(AAV) types 2, 5, and 6 in 
cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum. 
Gene Ther. 2006, 17, 440-447. 
117.  Antoni, B.A.; Rabson, A.B.; Miller, I.L.; Trempe, J.P.; Chejanovsky, N.; Carter, B.J. Adeno-
associated virus Rep protein inhibits human immunodeficiency virus type 1 production in human 
cells. J. Virol. 1991, 65, 396-404. 
118.  Schmidt, M.; Afione, S.; Kotin, R.M. Adeno-associated virus type 2 Rep78 induces apoptosis 
through caspase activation independently of p53. J. Virol. 2000, 74, 9441-9450. 
119. Yang, Q.; Chen, F.; Trempe, J.P. Characterization of cell lines that inducibly express the adeno-
associated virus Rep proteins. J. Virol. 1994, 68, 4847-4856. 
120.  Modlich, U.; Bohne, J.; Schmidt, M.; Von, K.C.; Knoss, S.; Schambach, A.; Baum, C. Cell-
culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 
2006, 108, 2545-2553. 
121.  Montini, E.; Cesana, D.; Schmidt, M.; Sanvito, F.; Ponzoni, M.; Bartholomae, C.; Sergi, S.L.; 
Benedicenti, F.; Ambrosi, A.; Di, S.C.; Doglioni, C.; Von, K.C.; Naldini, L. Hematopoietic stem 
cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector 
integration. Nat. Biotechnol. 2006, 24, 687-696. Viruses 2009, 1  
 
1323
122.  Allocca, M.; Doria, M.; Petrillo, M.; Colella, P.; Garcia-Hoyos, M.; Gibbs, D.; Kim, S.R.; 
Maguire, A.; Rex, T.S.; Di, V.U.; Cutillo, L.; Sparrow, J.R.; Williams, D.S.; Bennett, J.; 
Auricchio, A. Serotype-dependent packaging of large genes in adeno-associated viral vectors 
results in effective gene delivery in mice. J. Clin. Invest. 2008, 118, 1955-1964. 
123. Hockemeyer, D.; Soldner, F.; Beard, C.; Gao, Q.; Mitalipova, M.; DeKelver, R.C.; Katibah, G.E.; 
Amora, R.; Boydston, E.A.; Zeitler, B.; Meng, X.; Miller, J.C.; Zhang, L.; Rebar, E.J.; Gregory, 
P.D.; Urnov, F.D.; Jaenisch, R. Efficient targeting of expressed and silent genes in human ESCs 
and iPSCs using zinc-finger nucleases. Nat. Biotechnol. 2009, 27, 851-857. 
124. Ivics, Z.; Katzer, A.; Stuwe, E.E.; Fiedler, D.; Knespel, S.; Izsvak, Z. Targeted Sleeping Beauty 
transposition in human cells. Mol. Ther. 2007, 15, 1137-1144. 
125.  Yant, S.R.; Huang, Y.; Akache, B.; Kay, M.A. Site-directed transposon integration in human 
cells. Nucleic Acids Res. 2007, 35, e50. 
126.  Keravala, A.; Lee, S.; Thyagarajan, B.; Olivares, E.C.; Gabrovsky, V.E.; Woodard, L.E.; Calos, 
M.P. Mutational derivatives of PhiC31 integrase with increased efficiency and specificity. Mol. 
Ther. 2009, 17, 112-120. 
127.  Brown, B.D.; Naldini, L. Exploiting and antagonizing microRNA regulation for therapeutic and 
experimental applications. Nat. Rev. Genet. 2009, 10, 578-585. 
128.  Buchholz, C.J.; Muhlebach, M.D.; Cichutek, K. Lentiviral vectors with measles virus 
glycoproteins - dream team for gene transfer? Trends Biotechnol. 2009, 27, 259-265. 
129. Frampton, A.R., Jr.; Goins, W.F.; Nakano, K.; Burton, E.A.; Glorioso, J.C. HSV trafficking and 
development of gene therapy vectors with applications in the nervous system. Gene Ther. 2005, 
12, 891-901. 
130. Kwon, I.; Schaffer, D.V. Designer gene delivery vectors: molecular engineering and evolution of 
adeno-associated viral vectors for enhanced gene transfer. Pharm. Res. 2008, 25, 489-499. 
131. Van, V.K.; Mohiuddin, Y.; McClung, S.; Blouin, V.; Rolling, F.; Moullier, P.; gbandje-McKenna, 
M.; Snyder, R.O. Adeno-associated virus capsid serotype identification: Analytical methods 
development and application. J. Virol. Methods 2009, 159, 167-177. 
132. Yu, J.H.; Schaffer, D.V. Advanced targeting strategies for murine retroviral and adeno-associated 
viral vectors. Adv. Biochem. Eng. Biotechnol. 2005, 99, 147-167. 
133. Costantini, L.C.; Jacoby, D.R.; Wang, S.; Fraefel, C.; Breakefield, X.O.; Isacson, O. Gene transfer 
to the nigrostriatal system by hybrid herpes simplex virus/adeno- associated virus amplicon 
vectors. Hum Gene Ther. 1999, 10, 2441-2443.  
134.  Ueno, T.; Matsumura, H.; Tanaka, K.; Iwasaki, T.; Ueno, M.; Fujinaga, K.; Asada, K.; Kato, I. 
Site-specific integration of a transgene mediated by a hybrid adenovirus/adeno-associated virus 
vector using the Cre/loxP-expression-switching system. Biochem. Biophys. Res. Commun. 2000, 
273, 473-478. 
135. Broberg, E.K.; Hukkanen, V. Immune response to herpes simplex virus and gamma134.5 deleted 
HSV vectors. Curr. Gene Ther. 2005, 5, 523-530. 
136.  Follenzi, A.; Santambrogio, L.; Annoni, A. Immune responses to lentiviral vectors. Curr. Gene 
Ther. 2007, 7, 306-315. 
137. Seiler, M.P.; Cerullo, V.; Lee, B. Immune response to helper dependent adenoviral mediated liver 
gene therapy: challenges and prospects. Curr. Gene Ther. 2007, 7, 297-305. Viruses 2009, 1  
 
1324
138. Yant, S.R.; Park, J.; Huang, Y.; Mikkelsen, J.G.; Kay, M.A. Mutational analysis of the N-terminal 
DNA-binding domain of sleeping beauty transposase: critical residues for DNA binding and 
hyperactivity in mammalian cells. Mol. Cell Biol. 2004, 24, 9239-9247. 
139.  Baum, C.; Von, K.C.; Staal, F.J.; Li, Z.; Fehse, B.; Schmidt, M.; Weerkamp, F.; Karlsson, S.; 
Wagemaker, G.; Williams, D.A. Chance or necessity? Insertional mutagenesis in gene therapy 
and its consequences. Mol. Ther. 2004, 9, 5-13. 
140. Walisko, O.; Schorn, A.; Rolfs, F.; Devaraj, A.; Miskey, C.; Izsvak, Z.; Ivics, Z. Transcriptional 
activities of the Sleeping Beauty transposon and shielding its genetic cargo with insulators. Mol. 
Ther. 2008, 16, 359-369. 
141. Kuate, S.; Stefanou, D.; Hoffmann, D.; Wildner, O.; Uberla, K. Production of lentiviral vectors by 
transient expression of minimal packaging genes from recombinant adenoviruses. J. Gene Med. 
2004, 6, 1197-1205. 
142.Kubo, S.; Mitani, K. A new hybrid system capable of efficient lentiviral vector production and 
stable gene transfer mediated by a single helper-dependent adenoviral vector. J. Virol. 2003, 77, 
2964-2971. 
143.  Soifer, H.; Higo, C.; Logg, C.R.; Jih, L.J.; Shichinohe, T.; Harboe-Schmidt, E.; Mitani, K.; 
Kasahara, N. A novel, helper-dependent, adenovirus-retrovirus hybrid vector: stable transduction 
by a two-stage mechanism. Mol. Ther. 2002, 5, 599-608. 
144. Geurts, A.M.; Yang, Y.; Clark, K.J.; Liu, G.; Cui, Z.; Dupuy, A.J.; Bell, J.B.; Largaespada, D.A.; 
Hackett, P.B. Gene transfer into genomes of human cells by the sleeping beauty transposon 
system. Mol. Ther. 2003, 8, 108-117. 
145.Robert, M.A.; Benoit, R.; Desfosse, L.; Mairey, E.; Tremblay, J.P.  ; Massie, B.; Gilbert, R. 
Integration site mapping of linear and circular gutless adenovirus mediated by the phage phiC31 
integrase. In Abstract book of American Society of Gene Therapy, R.M. Frederickson: Seattle, 
WA, USA, 2009; p. S46. 
146. Niemeyer, G.P.; Herzog, R.W.; Mount, J.; Arruda, V.R.; Tillson, D.M.; Hathcock, J.; van Ginkel, 
F.W.; High, K.A.; Lothrop, C.D. Long-term correction of inhibitor-prone hemophilia B dogs 
treated with liver-directed AAV2-mediated factor IX gene therapy. Blood 2009, 113, 797-806. 
 
© 2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. 
This article is an open-access article distributed under the terms and conditions of the Creative 
Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). 
 